Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2003

01-07-2003

Quantitative Fluorescence Cytometric Measurement of Estrogen and Progesterone Receptors: Correlation with the Hormone Binding Assay

Authors: Angelos D. Gritzapis, Constantin N. Baxevanis, Ioannis Missitzis, Efrosine S. Katsanou, Michael N. Alexis, Julia Yotis, Michael Papamichail

Published in: Breast Cancer Research and Treatment | Issue 1/2003

Login to get access
Metadata
Title
Quantitative Fluorescence Cytometric Measurement of Estrogen and Progesterone Receptors: Correlation with the Hormone Binding Assay
Authors
Angelos D. Gritzapis
Constantin N. Baxevanis
Ioannis Missitzis
Efrosine S. Katsanou
Michael N. Alexis
Julia Yotis
Michael Papamichail
Publication date
01-07-2003
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1024462416640

Other articles of this Issue 1/2003

Breast Cancer Research and Treatment 1/2003 Go to the issue

OriginalPaper

High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival

OriginalPaper

Estrogen Receptor Alpha Gene Polymorphisms and Breast Cancer Risk

OriginalPaper

Expression of Estrogen Receptor-β in Normal Mammary and Tumor Tissues: is it Protective in Breast Carcinogenesis?

OriginalPaper

A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer

OriginalPaper

Pain and Quality of Life after Surgery for Breast Cancer

OriginalPaper

Vitamin D Growth Inhibition of Breast Cancer Cells: Gene Expression Patterns Assessed by cDNA Microarray
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits